TNNC1 and chronic kidney disease: Cheung et al. [31], using an IL-1 receptor agonist, demonstrated that anti-inflammatory therapy normalized Tnnc1, Tpm3 and Atp2a2 expression in the gastrocnemius muscle of mice with chronic kidney disease, suggesting a potential therapeutic approach for muscle wasting.